Doctor Explains How Weight Loss Drugs Can Lower Healthcare Costs

Increased Access to Weight Loss Drugs

• 💡 The announcement of a deal with Eli Lilly and Novo Nordisk aims to lower the cost of weight loss drugs for some Americans.
• 📌 Without insurance, these GLP1 medications can cost over $1,300 per month, but the new plan would start doses as low as $245 for one and $149 for another.

Impact on Public Health and Medicare/Medicaid

• 🎯 Increased access to these drugs can significantly benefit the 35 to 60 million beneficiaries of Medicare and Medicaid who currently lack access.
• 🏥 Beyond weight management, these medications can improve other health conditions such as heart disease, severe diabetes, and sleep apnea.

Efficacy Beyond Diet and Exercise

• 📉 Clinical trials show that diet and exercise alone typically result in only about 3% weight loss, which is often negligible for reducing long-term disease risk.
• 💊 Access to GLP1s can help reduce downstream Medicare and Medicaid costs associated with cardiac admissions, heart failure, severe diabetes, and other conditions.

Historical Restrictions and Current Understanding

• ⚠️ A law from the 90s, stemming from concerns about unsafe weight loss medications causing valvopathy, previously prevented CMS beneficiaries from covering weight loss drugs.
• ✨ Current GLP1 agonists are recognized not just for appetite suppression but for helping fat cells shrink and addressing the brain and gut pathway for weight loss, while also decreasing risks for various health issues.
• ✅ These medications are demonstrating safety and effectiveness for long-term use in trials and the general population.